Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
Authors:
- 25 January 2022
- journal article
- research article
- Published by Massachusetts Medical Society in NEJM Evidence
- Vol. 1 (2)
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferretsNature Microbiology, 2020
- Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceScience Translational Medicine, 2020
- Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to ResistanceJournal of Virology, 2019
- Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial VirusesAntimicrobial Agents and Chemotherapy, 2018
- β- d - N 4 -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral GenomeJournal of Virology, 2018
- The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) WorkgroupMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2015
- Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in CultureAntimicrobial Agents and Chemotherapy, 2003